Direct molecular analysis of myotonic dystrophy in the German population: important considerations in genetic counselling


Abstract
Myotonic dystrophy (DM) is associated with the expansion and instability of a trinucleotide (CTG) repeat at the DM locus on chromosome 19. Direct genomic analysis in the German population was carried out on 18 DM families, six families with equivocal diagnosis, 69 subjects with equivocal clinical diagnosis, and 100 controls using the polymerase chain reaction (PCR) and a refined Southern protocol.

In the majority of the cases molecular analysis confirmed the clinical diagnosis. These included seven cases of congenital DM (CDM) with widely differing gene expansions and instabilities. In most DM families the expanded fragment became larger in successive generations, but we also identified four families with contractions and two families that showed stability of the enlarged fragment during transmission.

In four clinically defined DM patients we were unable to detect enlarged CTG repeats. Sequencing of each exon of the DM gene in two of these patients failed to show any mutations.

Our cases have important implications for genetic counselling of DM families, highlighting both the diagnostic value of direct genomic analysis and its limitations.

DM is caused by the expansion and instability of a CTG trinucleotide repeat in the 3' untranslated region of a gene at 19q13.2–13.3, encoding a putative cAMP dependent protein kinase (DMFK). In the normal population the CTG copy number ranges from five to about 37, but in DM patients there are extreme expansions up to 4000 copies. There are no reports of the normal range overlapping with the minimal repeat number associated with the DM phenotype. There is a broad correlation of symptom severity with expansion size, although this is more readily observable within rather than between pedigrees.

In the majority of reported cases the CTG expansion increases in size with transmission in a DM pedigree. This may act as a molecular basis for anticipation, greater expansion sizes being generally associated with increasing symptom severity. However, there are a number of reports of contraction of the repeat upon transmission, mainly paternally. It is also possible that stable transmissions of relatively small expansions are underestimated owing to ascertainment biases.

The amplified CTG repeat region shows both meiotic and mitotic instability. The somatic mosaicism resulting from mitotic instability is characterised by a diffuse smear of fragments harbouring expanded repeats, occurring at least in blood leucocytes generally used for DNA extraction, whereas the differences in size within one generation of a DM family may be explained by meiotic instability of germline mosaicism.

Materials and methods
DNA ANALYSIS
Genomic DNA was isolated from peripheral blood samples according to Miller et al. The DNA was analysed for the expansion by Southern blotting using cDNA probes p3Bl1.4 and p25B1.4, as previously described. The probes were radiolabelled using [32P]-dCTP by random labelling. Expanded fragments were sized by measuring the midpoint of the band, and recording its upper and lower extremes, as larger bands tend to be diffuse owing to somatic heterogeneity.

PCR ANALYSES AND SEQUENCING
PCR amplification of the CTG repeat region was performed using the conditions described by Brook et al with primers 101 and 102, One
Expansion after 4-16-20

Table 1 PCR primers and conditions for amplification of all exons of the DMPK gene.
All the primers are located in intronic regions in order to generate the entire exons

<table>
<thead>
<tr>
<th>Exon(s)</th>
<th>Fragment size (bp)</th>
<th>Primer sequence (F=forward, R=reverse)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>668</td>
<td>5'-GTTGCTACTGGGTGACATCAGCCC-3'</td>
</tr>
<tr>
<td>2,3,4</td>
<td>750</td>
<td>5'-CTGCTTCCAATGGCCATTCTTCCTCT-3'</td>
</tr>
<tr>
<td>5,6</td>
<td>622</td>
<td>5'-CTGAGAGGACACTCAGGGA-3'</td>
</tr>
<tr>
<td>7,8</td>
<td>699</td>
<td>5'-TACGAGGACACTCAGGGA-3'</td>
</tr>
<tr>
<td>9</td>
<td>183</td>
<td>3'-TCTGCTGTCACATCCTGGTG-5'</td>
</tr>
<tr>
<td>10</td>
<td>198</td>
<td>5'-TCTGTCCTCCCTCTCCCACT-3'</td>
</tr>
<tr>
<td>11,12,13</td>
<td>781</td>
<td>5'-CCCTAGAGCTTCCTCTCCCC-3'</td>
</tr>
<tr>
<td>14</td>
<td>394</td>
<td>5'-ATCTCTCGTGCTTTAGCCGC-3'</td>
</tr>
<tr>
<td>15</td>
<td>721</td>
<td>5'-CCACCTAGGCTGCTAGGC-3'</td>
</tr>
</tbody>
</table>

PCR conditions: 200 ng genomic DNA, 50 pmol primer, 200 µmol dNTP, 67 mmol/l Tris-HCl, pH 8.8, 16.6 mmol/l (NH₄)₂SO₄, 2 mmol/l 2-5 mmol/l 67 mmol/l MgCl₂, 10 mmol/l β-mercaptoethanol, 0.7 µmol/l EDTA, 1 unit Taq polymerase in a total reaction volume of 50 µl. Initial denaturation step of 95°C for five minutes, followed by 30 cycles of 95°C for 40 seconds, 60°C for 90 seconds, 72°C for three minutes, with a final elongation step of 72°C for seven minutes.

PATIENTS

Twenty-four families (121 subjects) were investigated, comprising 18 families (108 subjects including 51 patients at risk) with a definite clinical diagnosis of DM (by the criteria of Griggs et al. and Koch et al.) and six families (13 subjects) with a clinically equivocal DM diagnosis. In the majority of cases full clinical data were available. In addition, blood samples from a further 69 subjects (35 of whom had received a definite clinical diagnosis of DM, and 34 an equivocal diagnosis) were analysed. These samples had been sent from neurological clinics throughout Germany for molecular diagnosis. The control group was composed of 100 healthy, randomly chosen volunteer donors from eastern Germany between 16 and 60 years of age, with an approximately equal ratio of males to females.

Results

CTG REPEAT ALLELE DISTRIBUTION IN THE CONTROL POPULATION

The distribution of alleles in the non-DM population showed no obvious differences from the previously reported figures for the European population (data not shown). The highest repeat number observed was 37 repeats.

EXPANDED DM ALLELES

Expansions of the CTG repeat were found in 18 families diagnosed clinically with DM. All patients with minimal symptoms had CTG expansions of less than 0.5 kb. Classical DM appears to be associated with a very wide range of expansion sizes, ranging from 0.6 kb to 5-7 kb. Of the seven congenitally affected patients in this study (table 2) three had very large expansions of over 5 kb, while four had smaller expansions, in a range which can also be associated with classical symptoms.

Extensive smearing was found on the Southern blots of the large expansions from the classically affected cases and in the adult CDM cases, suggesting widespread somatic heterogeneity in peripheral blood leucocytes. The smears ranged in size from 0-1 kb to 2-0 kb. Very little smearing could be detected for either the minimal expansions or, interestingly, for the three severely affected CDM neonates (table 2). These presented with very sharp expanded bands of approximately 5-5 kb, 5-4 kb, and 4-1 kb on Southern blotting, when using the restriction enzyme Bgl II (data not shown).

CHANGES IN CTG EXPANSION SIZE ON TRANSMISSION

In the 18 families available for study, increases in the size of the expanded fragment were found

Table 2 Analysis of transmission of congenital DM (CDM) in the German population. Expansion sizes were estimated by Southern blotting, using the enzyme Bgl II and probes p52B1.4 or p25B1.4. Sharp bands were detected in cases 3, 4, and 7. Family numbers are shown after the CDM case number, when the cases have appeared in other tables in this paper. The age at DNA sampling is given. Note the very small maternal expansion in case 1

<table>
<thead>
<tr>
<th>Family No</th>
<th>Expansion (kb)</th>
<th>Transmission change (kb)</th>
</tr>
</thead>
<tbody>
<tr>
<td>(A)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>4-7-5-7</td>
<td>1-2-1-7</td>
</tr>
<tr>
<td>14</td>
<td>3-5-4-0</td>
<td>1-3-1-8</td>
</tr>
<tr>
<td>15</td>
<td>1-7-2-1</td>
<td>0-6-0-8</td>
</tr>
<tr>
<td>16</td>
<td>1-9-2-1</td>
<td>0-4-0-1</td>
</tr>
<tr>
<td>(B)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>0-7-1-7</td>
<td>0-3-0-4</td>
</tr>
<tr>
<td>18</td>
<td>2-0-2-5</td>
<td>0</td>
</tr>
</tbody>
</table>

Note: In case 1, the maternal expansion is very small, estimated at 2-0-2-3.
in 12 families (data not shown), decreases were
found in four and in two families there were
no major changes in expansion size on trans-
mis sion. The sample numbers are too small
to determine if there is a statistically significant
difference in the pattern of transmission
through the male and female lines, as has been
previously reported. 20

The increases in expansion size range from
+0.3 kb to +3.7 kb and in these families there
is broad correlation between symptom severity
and the change in fragment size, although there
are interesting exceptions to this general trend.
In one family two sons with very similar sized
expansions in the DNA of their peripheral
blood leukocytes show marked differences in
their symptoms. Both have inherited ex-
pan sions of approximately 1–2 kb from their
minimally affected mother. The older son, who
is now 32 years old, first noticed clinical symp-
toms at 26 years of age, and has been diagnosed
as classically affected. His brother is two years
younger and is subjectively asymptomatic, al-
though slight myotonic signs on EMG and the
initiation of bilateral myotonic cataracts have
been noted clinically.

Table 3A contains the information on
which the expanded fragment either remained
stable or contracted in size on transmission. In
each of families 13 to 16 there is at least one
transmission event in which there has been a
decrease in fragment size, but in each case this
has been accompanied by clinical anticipation.
In one case, family 13, the child who has
inherited the contraction from his mother pre-
sented with CDM (CDM case 2, table 2). The
mother had first noticed muscle weakness at
13 years of age and myotonia at 16. She is now
54 years old and has severe classical DM, with
marked muscle involvement. She is unable to
walk. The son shown in table 3A was born with
CDM and is now 24 years old. His symptoms
include mental retardation, myotonia, cataract,
club foot, and other symptoms of classical DM.
He has no detectable myopathy.

In family 14, the mother shown in table 3A
has distinct myotonia and remarkable my-
opathy. She developed her symptoms in early
adulthood and is now unable to walk. Her 12
year old son, who has inherited a contracted
allele from her, has severe early childhood onset
DM, with mental retardation and an inability
to walk even today.

In families 17 and 18 there was considerable
overlap of the ranges of the expansions in the
affected family members and it was not possible
to show a clear trend in the behaviour of the
expansion in these pedigrees. Clinical antici-
pation was apparent in family 17, where the
father has classical DM with myotonia (only
detectable by EMG) and an age at onset of
approximately 40 years. The son, shown in
Table 3B, has remarkable myotonic discharges
on EMG and began presenting with classical
DM symptoms at the age of 17 years.

Owing to small family sizes we were unable
to investigate multiple transmission events in
these pedigrees. It is therefore unclear if the
predominant transmission of contractions/
stable expansions to sons is simply an artefact
of our data.

There were no examples in our families of
contractions from the pathological back into
the normal range.

**ANALYSIS OF EQUIVOCAL CASES**
In six families in which DM had been suggested
on clinical grounds no expansions of the CTG
repeat could be shown at the molecular level.
As a consequence the families were reanalysed
clinically and alternative diagnoses were made,
including Peno-Shokeir syndrome I (arthro-
gryposis multiplex congenita) and congenital
myopathy associated with malignant hyper-
thermia.

In certain cases we had access only to blood
samples from subjects with suspected DM; no
samples were available from other family
members. There were 69 such patients, of
whom 35 had been “definitely” diagnosed with
DM, and for the remaining 34 the clinical
diagnosis was equivocal. In the “equivocal”
group the DM diagnosis was confirmed for five
(14.7%) of these cases. In the remaining
patients in this group other diagnoses were
reached by the clinicians after receipt of this
molecular information. In the “definite” group
the diagnosis was confirmed in 31 patients
(88.6%). However, in the remaining four
patients two normal CTG alleles were present,
yet clinical reassessment after the molecular


<table>
<thead>
<tr>
<th>Case 1</th>
<th>Case 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myotonia</td>
<td>Grip (slight)</td>
</tr>
<tr>
<td>Muscle atrophy</td>
<td>Predominantly proximal</td>
</tr>
<tr>
<td>Serum CK</td>
<td>Normal</td>
</tr>
<tr>
<td>Muscle biopsy</td>
<td>Not performed</td>
</tr>
<tr>
<td>Ocular findings</td>
<td>Typical bilateral DM cataracts</td>
</tr>
<tr>
<td>Endocrine findings</td>
<td>Goitre</td>
</tr>
<tr>
<td>Gynaecology</td>
<td>Diabetes mellitus</td>
</tr>
<tr>
<td>Cardiac findings</td>
<td>Possible left ventricular hypertrophy</td>
</tr>
<tr>
<td>Mental retardation</td>
<td>Possible slight retardation</td>
</tr>
<tr>
<td>Other symptoms</td>
<td>Hyponatraemia</td>
</tr>
<tr>
<td>Age of onset</td>
<td>Upper limb myotonia at 30 y</td>
</tr>
<tr>
<td></td>
<td>Lower limb myotonia at 50 y</td>
</tr>
<tr>
<td></td>
<td>Weakness in 5th-6th decades</td>
</tr>
<tr>
<td>Family history</td>
<td>Hyper motonia in early 2nd decade</td>
</tr>
</tbody>
</table>

**Table 4. Major symptoms in two unrelated female patients with a clinical diagnosis of DM but no CTG expansion**
analysis still indicated DM as the most appropriate diagnosis. Clinical data for two of these four "non-expansion DM" patients are presented in table 4. Each exon of the DMPK gene was sequenced in these two patients but no mutations were detected.

Discussion
This study confirms and extends previous observations on both the normal and expanded DM alleles, focusing exclusively on the German population. It confirms previous reports that contraction of the repeat is a much more common phenomenon than had originally been expected, although in this case the numbers are too small to confirm the apparent male bias in this effect.

The data reported here clearly show that the correlation between expansion size and symptom severity is broad rather than absolute, illustrating the difficulties which surround not only prenatal diagnosis but also predictive estimation of disease severity based on expansion size. At its most extreme form transmission of a contracted allele was associated with clinical presentation with CDM, a phenomenon which has only been reported once previously, when an 8 kb expansion in a classically affected mother was transmitted as a 4 kb expansion to a congenitally affected child. The implications of this finding, particularly for prenatal diagnosis, cannot be overstressed. It is interesting that in all reported cases in which biopsy material has been analysed larger expansions have always been found in the muscle tissue than the blood of affected subjects. It would be interesting to examine the expansion in the muscles of the parent–child pairs in whom contractions have been associated with clinical anticipation. The symptomatically discordant brothers who have very similar repeat sizes would also be interesting subjects for an analysis of tissue heterogeneity, to determine if muscle expansions are more reliable predictive indicators.

The lack of detectable somatic heterogeneity in the peripheral blood leucocytes from neonatal congenital cases, compared with adult cases, may suggest that this heterogeneity is established after birth and may be a continuing process throughout life. It will be of great interest to perform a prospective longitudinal study on the expansion in the leucocytes from these congenital cases to determine at what point the somatic heterogeneity in this tissue becomes established, and whether it arises solely through continued enlargement of the expansion, contraction, or both. Interestingly, no detectable progression has been reported in muscle biopsy samples taken over a 15 year period, although it has yet to be formally proven that this lack of progression was not an artefact of the gel system used.

DM is considered one of the most genetically homogeneous diseases, with over 99% of cases being caused by the CTG expansion. There is very strong evidence for a founder chromosome effect in this disorder and no new mutations have been found. It is anticipated that in the cases reported here in which the expansion was identified in isolated cases other family members will almost certainly present with minimal expansions and very mild symptoms.

It was unexpected that in four of our cases in which no two normal alleles were identified at the DM locus there remained a clinically definite diagnosis of DM. As shown in table 4 these fulfill all recognised criteria for diagnosis of DM, and this remained the most appropriate clinical assessment at the point of examination. It is possible, however, that these patients may represent cases related to the recently described PROMM syndrome, in which an allele of a known mutation(s) underlying this disorder this hypothesis cannot be tested. The possibility also remains that these patients may represent a form of allelic heterogeneity for DM. In the fragile X syndrome of mental retardation, another of the trinucleotide repeat disorders, a case has been reported in which a point mutation within the FMR1 gene resulted in a phenotype identical to that caused by the trinucleotide expansion. However, in the patients presented here exonic sequencing of the entire DM gene failed to identify any mutations. Although we have not formally excluded the possibility of an abnormal intronic splice site mutation in these patients, our data suggest that mutations within the DMPK gene itself are unlikely to be the cause of a significant number of cases of clinical DM in which there is no CTG expansion. We are currently attempting to identify genes which are closely related to DM at the DNA sequencing level, and these will be analysed for mutations in these cases and PROMM-like patients. It will also be important to confirm that these patients do not represent somatic mosaics, in whom there has been an expansion of the CTG repeat in the affected tissues.

Work at Charing Cross and Westminster Medical School is funded by the Muscular Dystrophy Group of Great Britain, and the Central Research Fund of the University of London.

Direct molecular analysis of myotonic dystrophy in the German population


